摘要
[目的]探讨尿砷与乳腺癌的关联,并分析5,10-亚甲基四氢叶酸还原酶(MTHFR)rs1801133和甲硫氨酸合成酶(MTR)rs1805087多态性位点对其关联的影响。[方法]2009年10月至2010年7月对新诊断的240例乳腺癌患者及同时期同医院体检的246例年龄频数匹配对照进行问卷调查、尿样和血样收集。尿砷浓度采用电感耦合等离子体质谱(ICP-MS)检测;MTHFR rs1801133和MTR rs1805087基因型采用基质辅助激光解吸/电离飞行时间质谱(MALDI-TOF-MS)方法,在Sequenom平台检测。[结果]病例组和对照组尿砷含量差异无统计学意义(P=0.32)。rs1801133和rs1805087在病例组和对照组中基因型分布差异无统计学意义(P>0.05)。rs1801133和rs1805087与砷对乳腺癌发生风险不存在交互作用(P>0.05)。[结论]在本研究人群中,未发现尿砷与乳腺癌风险有关联,MTHFR rs1801133和MTR rs1805087位点对该关联的影响也无统计学意义。
[Purpose] To examine the association of arsenic with breast cancer risk,and further explored the modification effect of rs1801133 in 5,10-methylenetetrahydrofolate reductase（MTH- FR） gene and rs1805087 in methionine synthase（MTR） gene on the association. [Methodsl A total of 240 cases with breast cancer and 246 age-matched persons with cancer-free who attended health screening assessments were recruited from October 2009 to July 2010. Blood and urine speci- mens were collected before treatment for patients and after interview for controls. The urinary con- centrations of arsenic were measured by inductively coupled plasma mass spectrometry（ICP-MS） and genotypes of rs1801133 and rs1805087 were detected by a matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry （MALDI-TOF-MS） platform （Sequenom, San Diego, Cali- fornia, USA）. [Results] The difference of urinary arsenic between case group and control group was not statistically significant and neither was genotypes of rsl801133 and rs1805087. There was no interaction between rs1801133,rs1805087 and arsenic on breast cancer risk. [Conclusion] In this study,we do not find an association between arsenic with breast cancer risk,and there is no modi- fication effect of MTHFR rs 1801133 and MTR rs 1805087 on the association.
出处
《中国肿瘤》
CAS
2013年第6期436-441,共6页
China Cancer
基金
国家自然科学基金(81172759)
广东省大学生创新训练项目(1055812304)
